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Abstract
Background: Scalp acupuncture (SA) and repetitive transcranial magnetic stimulation (rTMS) are effective for
treating cerebral infarction. This study aims to examine the efficacy and safety of SA and electromagnetic
convergence stimulation (SAEM-CS), which was developed through collaboration between conventional medical
physicians and doctors who practice traditional Korean medicine. SAEM-CS was designed to improve function in
patients with cerebral infarction, compared to the improvement after conventional stroke rehabilitation, SA, and
rTMS therapeutic approaches.
Methods/design: This study is a prospective, outcome assessor-blinded, randomized controlled clinical trial with a
1:1:1:1 allocation ratio. Participants with motion or sensory disabilities caused by a first-time cerebral infarction (n =
60) that had occurred within 1 month of the study onset will be randomly assigned to control, SA, rTMS, or SAEM-
CS groups. All groups will receive two sessions of conventional rehabilitation treatment per day. The SA group will
receive SA on the upper limb area of MS6 and MS7 (at the lesional hemisphere) for 20 min, the rTMS group will
receive low-frequency rTMS (LF-rTMS) treatment on the hot spot of the M1 region (motor cortex at the
contralesional hemisphere) for 20 min, and the SAEM-CS group will receive LF-rTMS over the contralesional M1
region hot spot while receiving simultaneous SA stimulation on the lesional upper limb area of MS6 and MS7 for
20 min. SA, rTMS, and SAEM-CS treatments will be conducted once/day, 5 days/week (excluding Saturdays and
Sundays) for 3 weeks, for a total of 15 sessions. The primary outcome will be evaluated using the Fugl‐Meyer
Assessment, while other scales assessing cognitive function, activities of daily living, walking, quality of life, and
stroke severity are considered secondary outcome measures. Outcome measurements will be conducted at
baseline (before intervention), 3 weeks after the first intervention (end of intervention), and 4 weeks after
intervention completion.
Discussion: This study aims to explore the efficacy and safety of SAEM-CS on cerebral infarction. Collaborative
research combined traditional Korean and conventional medicines, which can be useful in developing new
treatment technologies.
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Background
Cerebral infarction (CI) is one of the most commonly
reported cerebral vascular diseases, accounting for
about 70 % of strokes [1]. The incidence, mortality,
and recurrence rates of CI are high, and CI usually
leads to serious damage of the central nervous system
[2]. Despite a considerable amount of research on
effective treatments for stroke, there is still no single
intervention that clearly and definitively contributes
to stroke recovery. Therefore, stroke treatment strat-
egies should combine multiple disciplines, such as
neurology, rehabilitation medicine, and traditional
medicine [3]. Scalp acupuncture (SA) is one of several
specialized acupuncture techniques, and it involves a
filiform needle being used to penetrate specific stimu-
lation areas on the scalp [4]. SA therapy for ischemic
and hemorrhagic stroke has been empirically estab-
lished and is used worldwide [5–8]. The local applica-
tion of repetitive transcranial magnetic stimulation
(rTMS) influences the neural excitability of selected
brain areas [9], and it has been reported that low-
frequency stimulation (1 Hz) suppresses local neural
activities [10, 11], whereas high-frequency stimulation
(≥5 Hz) activates local neural activities [12]. Both
high-frequency rTMS (HF-rTMS) applied to the
lesional hemisphere and low-frequency rTMS (LF-
rTMS) applied to the contralesional hemisphere are
beneficial for upper limb hemiparesis in patients with
chronic stroke [11, 13–17] and in the early phase of
stroke [9, 18–20].
Conventional medical physicians and doctors who
practice traditional Korean medicine (TKM) tend to
focus on each field’s treatment methods in separate
medical systems. Unfortunately, efforts to improve the
treatment rates of incurable diseases through collabora-
tive research and via the fusion of treatment techniques
are lacking. The purpose of this study is to explore the
efficacy and safety of SA and electromagnetic conver-
gence stimulation (SAEM-CS), which was developed
through a collaborative study between the Department
of Physical and Rehabilitation Medicine at Chonnam
National University Hospital and the Departments of
Acupuncture and Moxibustion Medicine and Trad-
itional Korean Medicine Rehabilitation at Dong-Shin
University. Thereafter, we will compare SAEM-CS to




The objective of this study is to compare the efficacy of
SAEM-CS on motor function recovery to physical ther-
apy, rTMS, and SA. Further, we aim to explore the syn-
ergistic effect of converging SA and rTMS, which are
known to be effective in promoting the recovery of
motor function, in patients with CI.
Study design
This study is a prospective, outcome assessor-blinded,
single-center, randomized controlled clinical trial with
a 1:1:1:1 allocation ratio. This study is a pilot study
to investigate the efficacy and safety of SAEM-CS,
which is a newly developed treatment. This study is
designed as a single-center study to overcome several
procedural and organizational difficulties in terms of
developing a research team, since SAEM-CS involves
the simultaneous conduction of SA and rTMS. Partic-
ipants (n = 60) who fit the inclusion and exclusion cri-
teria will be randomly allocated into a control group
(n = 15), SA group (n = 15), rTMS group (n = 15), and
SAEM-CS group (n = 15). All groups will receive con-
ventional stroke rehabilitation therapy twice/day, five
times/week (excluding Saturdays and Sundays), for a
total of 15 times over the course of a 3-week
hospitalization period at Chonnam National University
Hospital. In addition, the SA group will receive SA ther-
apy, the rTMS group will receive rTMS therapy, and the
SAEM-CS group will receive SAEM-CS therapy once/day.
Outcome measures will be determined at baseline (before
intervention), 3 weeks after the first intervention (end of
the intervention), and 4 weeks after completion of the
intervention.
This study was approved by the Ministry of Food and
Drug Safety (MFDS), Medical Device Clinical Trial Plan
Approval number 516. (See Additional file 1.)
The study design is summarized in Table 1 and Fig. 1.
Participant recruitment
For achieving adequate participant enrollment to reach
target sample size, all stroke patients admitted to the
Department of Neurology of Chonnam National University
Hospital will be screened by Physical and Rehabilitation
Medicine doctors. From among the first-ever patients with
CI who are hospitalized and have finished treatment of
early acute stage CI at the Department of Neurology, those
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who are assessed as stable by a neurologist and meet the in-
clusion and exclusion criteria will be recruited for participa-
tion in this study.
Patients who are given an explanation about this study
by the Clinical Research Coordinator (CRC) and who
voluntarily sign a consent form will be transferred to the
Department of Physical and Rehabilitation Medicine to
participate in this study (see Additional file 2). The CRC
will continuously monitor the medical conditions of en-
rolled participants to improve adherence to intervention
protocols.
Inclusion criteria
Patients who meet all of the following conditions will be
considered for enrollment: patients who are aged
>19 years; who have incipient CI confirmed by a com-
puted tomography or magnetic resonance imaging
examination; who are diagnosed by a neurologist or
neurosurgeon; who experience a CI that resulted in
motor and sensory disorders within 1 month of the
study onset; who can undergo rehabilitation therapy
after hospitalization in the Department of Physical and
Rehabilitation Medicine, Chonnam National University
Table 1 Treatment schedule and outcome measures
FMA Fugl-Meyer Assessment, NIHSS National Institutes of Health Stroke Scale, MBI Modified Barthel Index, FIM Functional Independence Measurement, K-MMSE
Korean Mini-Mental State Examination, 9HPT 9-Hole Peg Test, ASHA-NOMS American Speech-Language-Hearing Association National Outcomes Measurement
System, FAC Functional Ambulation Categories, EQ-5D European Quality of Life-5 Dimensions, MAS Modified Ashworth Scale, MEP motor evoked potential, mRS
modified Rankin Scale
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Hospital; who have a modified Rankin Scale (mRS) score
of 2–4; and who voluntarily sign an informed consent
form.
Exclusion criteria
Subjects whose general condition is not good or fit for
SA and rTMS therapies will be excluded. Additional
exclusion criteria are as follows: history of brain lesion
(e.g., stroke, serious mental illness, loss of consciousness
accompanied by head trauma, brain surgery, or seizure
disorder); presence of other serious illnesses (e.g., cancer,
Alzheimer’s disease, epilepsy, head trauma, or cerebral
palsy); transient ischemic attacks; contraindications to
electro-magnetic stimulation (e.g., metal implants in the
brain, implanted electronic devices in the body, such as
non-detachable ferromagnetic metals, metal-sensitive
implants less than 30 cm away from the brain like coch-
lear implants, pacemakers, aneurysm clips or coils,
stents, bullet fragments, deep brain stimulation, vagus
nerve stimulators, jewelry, or hairpins); continuous con-
vulsion symptoms; previous craniectomy or shunt sur-
gery; elevated intracranial pressure symptoms such as
headache, vomiting, nausea, etc.; seizure disorder or epi-
lepsy after CI; history of stroke accompanied by a clear
clinical sign; contraindications to SA (e.g., scalp scarring,
inflammation from scalp injury, or infection in the treat-
ment region, inability to stop blood flow due to clotting
disturbances, such as hemophilia, etc., serious unusual
response after acupuncture treatment); women who are
pregnant or breastfeeding; patients who disagree with
the informed consent; and individuals scheduled for sur-
gery within 2 weeks.
Ethical considerations
The Institutional Review Board of Chonnam National
University Hospital approved this study (CNUH-2015-
114; see Additional file 3). The purpose and potential
risks of this clinical trial will be fully explained to the
patients and their families. All patients will be asked to
provide written informed consent before participating in
this study.
Randomization
After signed informed consent and baseline measure-
ments are obtained, random allocation software (devel-
oped by M. Saghaei, M.D., at the Department of
Anesthesia, Isfahan University of Medical Sciences,
Isfahan, Iran) is used to assign a serial number to the 60
research volunteers and to randomly allocate 15 of them
into each group. The serial number codes will be
inserted into sealed, opaque envelopes, kept in a double-
locked cabinet, and opened in the presence of the pa-
tient and a guardian.
Fig. 1 Study design flow chart
Han et al. Trials  (2016) 17:490 Page 4 of 11
Implementation
A CRC will generate the allocation sequence, enroll par-
ticipants, and assign participants to interventions.
Blinding
We have no choice but to adopt a single blinding (out-
come assessor blinding) approach, as sham treatment —
where participants and practitioners are not aware of the
treatment condition — is impossible due to the charac-
teristics of scalp acupuncture which include scalp pene-
tration. Efforts to maintain objectivity are made by
separating the CRC who manages the treatment sched-
ules, the practitioner who conducts the treatments, and
the assessor. During the course of this clinical trial, the
assessor will not come into contact with any of the par-
ticipants except at the time of assessment. Further, there
is no circumstance where unblinding will be permitted.
To prevent risks of bias, such as selection, performance,
and attrition caused by non-blinding of participants and
practitioners, only individuals without conflicts of inter-
est or preconceived positions are involved in this study.
All practitioners will receive training in clinical trials
prior to participation in this study.
Intervention
All participants will receive occupational therapy, which
focuses on practicing fine and gross motor movements,
activities of daily living, task-oriented therapeutic exer-
cises, and muscular electrical stimulation therapy, as
needed. Training for swallowing and to improve lan-
guage will be also performed for dysarthria. These ses-
sions will be conducted for 30 min, twice daily
(excluding Saturdays and Sundays) for 3 weeks, for a
total of 15 times. SA, rTMS, and SAEM-CS therapies
will be conducted once daily for 20 min (excluding
Saturdays and Sundays) for 3 weeks, for a total of 15
times (see Table 2).
The SA therapy method will be conducted as follows:
one or two needles are horizontally inserted about 3 cm
deep at the lesion site and upper limb regions of MS6
(line connecting GV21 and GB6) and MS7 (line con-
necting GV20 and GB7) [8] under the Standard Inter-
national Nomenclature in the direction from GV21 to
GB6 and GV20 to GB7. Manual stimulation and electro-
acupuncture are not applied, and the needles (KOS-92
non-magnetic steel acupuncture needles; size 0.25 mm ×
30 mm; Dong Bang Acupuncture, Inc., Boryeong,
Republic of Korea; Product no: A84010.02) (see Table 3)
are left in position for 20 min (see Table 4).
The rTMS method will be conducted as follows: a 70-
mm figure 8 coil and a Magstim Rapid stimulator
(Magstim Co., Dyfed, UK) is used to deliver 1 Hz of
rTMS to the skull of the contralesional hemisphere at
the site that elicits the largest motor evoked potentials
(MEPs) in the first dorsal interosseous (FDI) muscle of
the unaffected upper limb. One LF-rTMS session con-
sists of 1200 pulses and lasts for 20 min. The stimulation
intensity is set to 80 % of the motor threshold of the
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Table 3 KOS-92 alloy distribution
Type C Si Mn P S Ni Cr N Mo Other Note
STS304 0.08 1.0 2.0 0.045 0.03 8–10.5 18–20
STS304N1 0.08 1.0 2.5 0.045 0.03 8–10.5 18–20 0.1–0.25
STS316 0.08 1.0 2.0 0.045 0.03 10–14 16–18 2–3
KOS-92 0.08 1.0 10 0.03 0.03 5–6 17–18 0.25–0.35 Non-magnetic
Unit: %




1a) Style of acupuncture Korean medicine therapy
1b) Reasoning for treatment provided, based on historical
context, literature sources, and/or consensus methods, with
references where appropriate
1) Discussion among four doctors who practice Korean medicine
(consensus)
2) Textbook of acupuncture and moxibustion medicine
3) Relevant articles [7, 8]
Selection of treatment regions based on textbooks, related
papers, and expert discussions
1c) Extent to which treatment varied Standardized treatment
2. Details of
needling
2a) Number of needle insertions per subject per session
(mean and range where relevant)
2–4
2b) Names (or location if no standard name) of points used
(uni-/bilateral)
SIAN’s MS6; MS7 of the lesional hemisphere
2c) Depth of insertion, based on a specified unit of
measurement or on a particular tissue level
Needles were horizontally inserted into the subcutaneous tissue
of the scalp, about 3 cm deep.
2d) Responses sought No de qi or muscle twitching — only sensation due to needle
insertion
2e) Needle stimulation None
2f) Needle retention time 20 min per session
2 g) Needle type KOS-92 non-magnetic steel disposable needles (0.25-mm




3a) Number of treatment sessions 15




4a) Details of other interventions administered to the
acupuncture group
Conventional stroke rehabilitation therapy
4b) Setting and context of treatment, including instructions to
practitioners, as well as information and explanations given to
patients
Practitioner-patient conversation about the context of the
treatment, life habits, and daily life management
5. Practitioner
background
5) Description of participating acupuncturists Korean medicine doctor with the following qualifications:
6 years of formal university training in Korean medicine, a




6a) Rationale for the control or comparator in the context of
the research question, with sources that justify the choice
Wang Y, Shen J, Wang XM, Fu DL, Chen CY, Lu LY, et al. Scalp
acupuncture for acute ischemic stroke: a meta-analysis of
randomized controlled trials. Evid Based Complement Altern Med
2012;2012:480950; Lee SJ, Shin BC, Lee MS, Han CH, Kim JI. Scalp
acupuncture for stroke recovery: a systematic review and meta-
analysis of randomized controlled trials. European J Integr Med.
2013;5:87–99
6b) Precise description of the control or comparator; details for
items 1–3 above with the use of sham acupuncture or any
other type of acupuncture-like control
Conventional stroke rehabilitation therapy for control, rTMS, and
SAEM-CS groups. LF-rTMS applied to the hot spot of the M1
region (the motor cortex at the contralesional hemisphere) for the
rTMS group and LF-rTMS applied to the same M1 and simultaneous
SA stimulation over the upper MS6 and MS7 regions of the lesional
hemisphere for the SAEM-CS group
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FDI muscle, which is defined as the lowest intensity of
stimulation that provokes MEPs [15, 16]. All patients sit
in a reclining wheelchair and are asked to relax as much
as possible, with their heads strapped to a headrest [9].
The SAEM-CS treatment method will be conducted as
follows: the above-described SA and LF-rTMS therapies
are performed simultaneously. After SA treatment of
MS6 and MS7 on the lesion side, LF-rTMS stimulation
is conducted on the contralateral hemisphere of the
opposite side of the lesion for 20 min (Fig. 2).
The SA therapy will be conducted by a doctor who is
experienced in Korean medicine, is affiliated with Dong-
Shin Traditional Korean Medicine University Hospital,
and has more than 2 years of clinical experience. rTMS will
be conducted by a doctor affiliated with the Department of
Physical and Rehabilitation Medicine at Chonnam National
University Hospital.
During the clinical trial period, all participants are
allowed routine management, existing medications
(medications for hypertension, diabetes, hyperlipidemia,
and improvement of brain function), and medications to
maintain and improve health status. However, patients
are not allowed to engage in treatments to improve CI
other than the therapies used in this study.
All medical devices will be inspected by coordinators
who will manage scalp acupuncture needles (Min-yeong
Song, Resident of Department of Korean Medicine
Rehabilitation, College of Traditional Korean Medicine,
Dong-Shin University) and rTMS (Eom-ji Kim, occupa-
tional therapist, Department of Physical and Rehabilitation
Medicine at Chonnam National University Hospital).
Coordinators will record the results of the check-ups in
the management register.
Outcome measurements
Primary and secondary outcome assessments will be
conducted at baseline (before intervention), 3 weeks
after the first intervention, and 4 weeks after completion
of intervention.
Primary outcome
Since the objective of this study is to investigate the effi-
cacy of SAEM-CS on motor function recovery in pa-
tients with cerebral infarction, the primary outcome will
be assessed via changes on the Fugl‐Meyer Assessment
(FMA) scale for motor function. The FMA is widely
used as a qualitative measure of motor function and is
used in the current study to assess upper and lower limb
function. The FMA is categorized into 50 items based
on a six-stage recovery process of Brunnstrom’s hemi-
plegia classification and progress record. This assess-
ment is an ordinal scale, in which 0 is given for unable
to perform, 1 for partial performance, and 2 for
complete performance. The FMA has a possible total
score of 100, 66 points of which apply to the upper
limbs and 34 points to the lower limbs [16].
Secondary outcomes
Secondary outcome measures will be assessed
changes in the National Institutes of Health Stroke
Scale (NIHSS) score, Modified Barthel Index (MBI),
Functional Independence Measurement (FIM) score,
Korean Mini-Mental State Examination (K-MMSE)
score, American Speech-Language-Hearing Associ-
ation National Outcomes Measurement System
(ASHA-NOMS) Swallowing Scale score, Functional
Ambulation Categories (FAC), European Quality of
Life-5 Dimensions (EQ-5D), Modified Ashworth
Scale (MAS) score, Hand Grip Strength Test, MEPs,
mRS score, and 9-Hole Peg Test (9HPT).
The NIHSS is a scale that was developed by the
United States National Institutes of Health, and provides
useful information on the severity, prognosis, and early
treatment of stroke [9].
The MBI is an assessment tool used to objectively
evaluate performance of everyday movements on 10
Fig. 2 Application of SAEM-SC. LF-rTMS over the M1 region hot spot
(motor cortex at the left hemisphere) and SA stimulation of MS6
and MS7 at the upper limb regions of the right hemisphere
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items: personal hygiene, bathing, eating, toilet use, ability
to climb stairs, ability to dress, bowel/bladder function,
walking function, capability of getting into and out of a
chair/bed, and mobility [21].
The FIM is an assessment of everyday movement per-
formance that evaluates 13 detailed items of motor FIM
and 5 detailed items of cognitive FIM. The FIM has a
total possible score of 18–126, and each item is divided
into seven stages, allowing for a comparably detailed as-
sessment. Higher FIM scores indicate higher functional
independence [22].
The MMSE is a brief global instrument used to assess
cognitive abilities and has been translated into Korean
(K-MMSE) [23]. The K-MMSE is a quick screening as-
sessment tool that was developed to evaluate cognitive
function and dementia in elderly patients with suspected
dementia or patients with brain damage. The instrument
consists of measures used to assess orientation, recall,
attention and calculation, language, judgment, and un-
derstanding. A score ≥24 points indicates definitive nor-
mal, 20–23 indicates suspected dementia, and ≤19
indicates definitive dementia [24].
The ASHA-NOMS is a seven-stage dysphagia scale
developed by the American Speech-Language-Hearing
Association to evaluate severity of dysphagia for items
such as parenteral hyperalimentation, whether independ-
ent eating is possible, use of compensative skills for eat-
ing, and diet limitations [25].
The FAC is designed to evaluate walking ability where
a patient’s independent walking ability is categorized into
six ranks: 0 = unable to walk, 1 = direct assistance re-
quired by the therapist, 2 = intermittent and direct as-
sistance required by the therapist, 3 = able to walk
independently but requires observation, 4 = able to walk
independently but requires assistance on uneven
surfaces, and 5 = able to independently walk on even
surfaces [26].
The EQ-5D evaluates quality of life in five fields in-
cluding exercise ability, self-management, daily activities,
pain/discomfort, and anxiety/depression. Each field is di-
vided into three levels with 1 indicating a good state of
health. The EQ-5D also includes a visual analog scale in
which a subject indicates subjective and overall individ-
ual health status on a vertical scale where the best health
state is 100 points and the poorest health state is 0
points [27].
The MAS assesses muscles by measuring spasticity in
the wrist and elbow joints while the joints are maximally
bent. Scores range from 0, where there is no increase in
muscle tone, to 4, where there is contracture in bent and
straight muscles and/or joints [15].
The Hand Grip Strength Test evaluates muscle strength
in the hands and is conducted twice in six stages; the
higher value (kg) of the two tests is recorded [9].
In the current study, MEPs are evoked by stimulating
the primary motor cortex on representation of hand grip
muscles without pain, and responses of the FDI muscle
are then observed. MEPs are useful to predict functional
recovery in CI. Here, the cerebral hemisphere is magnet-
ically stimulated in a figure 8 shape while the patient is
lying down. Stimulations increase in intensity from 0 to
100 % until the MEP with the shortest latency occurs.
The latency and the amplitude of the MEP responses are
recorded [28].
The mRS is a six-point, ordinal hierarchical scale that
describes “global disability” with a focus on mobility.
The mRS is often used in contemporary stroke studies
as a measure of premorbid ability and is used to assist in
the selection of patients and as a final outcome measure.
The mRS uses a 5-min non-standardized interview, and
has six potential scores (0–5), which describe a full
range of stroke outcomes; a score of 6 denotes death
[29, 30].
The 9HPT is useful in measuring dexterity in relatively
well-recovered patients. In the current study, partici-
pants are instructed to place nine pegs into nine holes
on a board as fast as possible. Scores are computed as
pegs/s, averaged over three trials, and normalized to the
average score of the unaffected hand (range 0–1; 0 =
cannot do) [31].
Incidence of adverse events
Adverse events refer to undesirable and unintentional
signs, symptoms, or diseases that appear after treatment
in a clinical trial. Importantly, these events may not have
a causal relationship with the therapy employed; never-
theless, they should be documented. Adverse events ex-
pected from this study include nausea, vomiting,
headaches, dizziness, skin irritation, convulsions, and
objective worsening of existing symptoms. The CRC will
record adverse events, their progress, and their causal
relationship with treatments in detail and will report
them to the principal investigator (PI) and Institutional
Review Board (IRB). If serious adverse events occur, de-
fined as those causing severe disability or malfunction,
then appropriate measures will be taken and incidents
will be immediately reported to the PI and IRB.
Sample size
The sample size was calculated based on Cohen’s for-
mula. As there are very few precedent studies that have
conducted SAEM-CS similar to the present study, and
because characteristics of the variables being tested are
diverse, it was difficult to select and apply a single effect
size. Thus, we set the effect size as 0.25 based on a
medium f, which is one of Cohen’s criteria [32]. Accord-
ingly, we have established the number of groups as 4,
number of repetitions as 3, effect size as 0.25,
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significance level as 0.05, and statistical power as 0.8.
Therefore, the total sample size required for a repeated
measures ANOVA (taking into account interaction time
with the treatment method), calculated using G*power,
is 40 (10/group) [33].
Also, because the present study is an exploratory
clinical trial, we determined that a total of 60 partici-
pants, 15 in each group, would be more appropriate.
We based this on a previous study that recommended
12 participants per group for pilot studies that lack
prior information [34] and other conditions used to
determine the sample size for a pilot study [35] that
gave a sample size of 12 per group, to which a drop-
out rate of 25 % was applied. In order to minimize
the dropout, the CRC will manage the treatment
schedule of subjects.
Moreover, we considered the feasibility of the study,
since participants will be patients with CI (which, as
of 2014 average 46 per month) being treated at the
Department of Neurology at the Chonnam National
University Hospital. Considering the fact that among
them, only 10–20 % will receive inpatient treatment
at the Department of Rehabilitative Medicine and
meet the selection criteria, it reaffirmed our estima-
tion that 60 participants would be appropriate and
feasible to achieve the study objectives. This also
takes into account recruitment, study period, and
drop-out possibilities.
Data monitoring
The Data Monitoring Committee (DMC) is composed of
the PI and coordinators who are in charge of scalp acu-
puncture needles (Min-yeong Song, resident of the
Department of Korean Medicine Rehabilitation, College
of Traditional Korean Medicine, Dong-Shin University)
and rTMS (Eom-ji Kim, an occupational therapist in the
Department of Physical and Rehabilitation Medicine at
Chonnam National University Hospital). If needed, they
will report the monitoring results to the PI. Finally, this
study is independent from any sponsors.
Data analysis
Continuous data will be presented as means and stand-
ard deviations, while categorical data will be presented
as frequencies and percentages. A repeated measures
ANOVA will be conducted for the FMA and all second-
ary outcomes (NIHSS, MBI, FIM, K-MMSE, 9HPT,
ASHA-NOMS, FAC, EQ-5D, MAS, Hand Grip Strength,
and MEPs). Dependent variables include measured
values before and after intervention and the measured
values 4 weeks after completion of intervention. An F
test will be conducted to detect differences between
therapies, and Tukey’s post hoc test will be conducted to
identify the groups. Repeated contrast tests will be
conducted to account for time differences in each group,
and the interaction group and time test will be con-
ducted. A p value of <0.05 will be considered significant,
and participants who drop out of the study will be ex-
cluded from the analysis. In brief, only complete case
analyses will be used; thus, only subjects who complete
the three evaluations will be analyzed. All statistical ana-
lyses will be performed using SPSS version 22.0 software
(SPSS Inc., Chicago, IL, USA).
Data from participants who engage in less than 70 %
of protocol adherence (i.e., receive <10 treatments from
15 trials) will be eliminated. Missing values will be im-
plemented by multiple imputations. In addition, statis-
tical differences will be verified by comparing attribution
between eliminated and completed participants to check
particular factors causing drop-out.
Confidentiality and data management
Participant identification records will be kept confiden-
tial until the results of this study are published. All doc-
uments related to a clinical trial, such as case report
forms (CRFs), will be recorded and labeled with partici-
pant identification codes and will not show the name of
the participant. The serial number codes will be inserted
in sealed, opaque envelopes, kept in a double-locked
cabinet, and opened in the presence of the patient and a
guardian.
All data of the participants will be recorded in Excel
files by the CRC. Additionally, raw data (CRFs) will be
kept in a cabinet until the end of this study.
Written informed consent will be obtained from the
participants for publication of their individual details
and accompanying images in this manuscript. The con-
sent forms will be available for review by the Editor-in-
Chief.
Discussion
This protocol, following the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
advice and Consolidated Standards Of Reporting
Trials (CONSORT) 2010 guidelines, is designed to ex-
plore the synergistic effect of SAEM-CS on the recov-
ery of motor function in patients in the acute stage
of CI [36] (Additional file 4). We expect that rTMS
will enhance the effect of SA and compensate for a
commonly encountered problem in SA treatment:
specifically, difficulty in twirling the acupuncture nee-
dle (as these needles should be twirled more than 200
times/min).
SAEM-CS is a treatment technique that combines LF-
rTMS over the M1 region hot spot (motor cortex at the
contralesional hemisphere) and SA stimulation of MS6
and MS7 at the upper limb regions of the lesional hemi-
sphere to promote optimal functioning in patients
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following stoke. Despite other research showing that
HF-rTMS applied to the lesional hemisphere more
effectively improves motor function than LF-rTMS
applied to the contralesional hemisphere in the early
phases of stroke [9], LF-rTMS is selected for the com-
bined SAEM-CS approach because there is some con-
cern about complications that can arise due to the
simultaneous use of SA and rTMS in the same hemi-
sphere, and since we cannot completely exclude the
interfering effects of HF-rTMS, even with non-magnetic
needles. rTMS creates a powerful magnetic field near
the stimulated area; therefore, all metal materials must
be removed [37]. For rTMS and SA therapies that are
conducted simultaneously (during SAEM-CS), we use a
KOS-92 non-magnetic steel acupuncture needle that
contains a much higher percentage of nitrogen (N) than
STS304N1; thus, even in high processing volumes, the
needle has no magnetic properties. The same method
used in the SAEM-CS approach is employed for the SA
and rTMS therapies. Thus, manual stimulation and elec-
troacupuncture are not conducted in the SA group, and
LF-rTMS is applied to the contralesional hemisphere in
the rTMS group.
In the current study, we select patients hospitalized
within 1 month after acute stroke in order to increase
the homogeneity of the experimental population. This
period was also chosen to increase reliability, because
the most important period of recovery falls within the
acute and subacute stages of ischemic stroke [38].
We expect that SAEM-CS will improve motor function;
therefore, the FMA was selected as the primary outcome
measure. In order to investigate unexpected effects of
SAEM-CS, other scales assessing cognitive function, activ-
ities of daily living, walking, quality of life, and stroke se-
verity are employed as secondary outcome measures.
Among TKM and CM professionals, there is a general
lack of cooperation for developing techniques aimed to
treat obstinate diseases. If the efficacy and safety of the
above-described SAEM-CS approach is proven, it will
serve as a model for collaborative research and will pro-
mote CM and TKM professionals to fuse therapeutic
techniques. One hopes that such approaches can im-
prove the treatment rates of incurable diseases.
Dissemination policy
We will report the final data to the Ministry of Health
and Welfare through the Korea Health Industry
Development Institute, and we will publish the results
at the end of this study.
Trial status
This trial is ongoing. Enrollment and trial completion
are expected to be finished by the end of May 2017.
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